Related Experiment Videos
[Stem cell concentrates in autologous transplantation]
J Zingsem1, T Zeiler, V Weisbach
1Abteilung Innere Medizin, Universitätsklinikum Rudolf Virchow, Standort Charlottenburg, Freie Universität Berlin.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1990
Summary
Peripheral blood stem cells (PBSC) offer a promising alternative to autologous bone marrow transplantation for leukemia patients. PBSC transplantation resulted in shorter cytopenic periods and successful disease-free survival.
Area of Science:
- Hematology
- Oncology
- Transplantation immunology
Context:
- Autologous bone marrow transplantation (ABMT) is a standard treatment for leukemic diseases.
- Peripheral blood stem cell (PBSC) transplantation is increasingly utilized as an alternative to ABMT.
- PBSC collection involves cytapheresis procedures.
Purpose:
- To evaluate the efficacy and outcomes of PBSC transplantation compared to ABMT in leukemic patients.
- To assess peripheral blood mononuclear cell (PBM) and colony-forming unit-granulocyte-macrophage (CFU-GM) recoveries during cytapheresis.
- To analyze post-transplantation recovery and disease-free survival in a patient receiving PBSC alone.
Summary:
- A discontinuous flow separation technique (Haemonetics V50, Lymphosurge) achieved 74% PBM recoveries in healthy donors.
- PBSC collected from 4 leukemic patients (3 AML, 1 ALL) over 28 procedures showed mean CFU-GM recoveries of 66%.
- One patient transplanted with PBSC alone experienced shorter post-transplantation cytopenia and over eight months of disease-free survival.
Impact:
- PBSC transplantation demonstrates potential for improved patient recovery and reduced treatment-related morbidity.
- Successful engraftment and sustained remission suggest PBSC as a viable alternative to ABMT.
- This approach facilitates faster patient reintegration into social and working life.